Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Agnostic material classification using differential de Bruijn graphs of DNA imprints.

bioRxiv : the preprint server for biology·2026
Same author

The Origin of Life in the Light of Evolution.

ArXiv·2026
Same author

Overestimating zero-shot fitness prediction: Broad benchmarks mask local failures and practical limitations.

bioRxiv : the preprint server for biology·2026
Same author

Integrating Transcription Factors with Electrochemical Pendulum Bioanalysis for Hormone Detection.

Journal of the American Chemical Society·2026
Same author

Fieldable isothermal nucleic acid test for rapid semi-quantitative visual readout of enterococci in recreational waters.

PeerJ·2026
Same author

Validation and analysis of 12,000 AI-driven CAR-T designs in the <i>Bits to Binders</i> competitions.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jun 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Aptamers that recognize drug-resistant HIV-1 reverse transcriptase.

Na Li1, Yuxuan Wang, Arti Pothukuchy

  • 1Department of Chemistry and Biochemistry, Institute for Cell and Molecular Biology, University of Texas at Austin, Austin, TX 78712, USA.

Nucleic Acids Research
|October 25, 2008
PubMed
Summary
This summary is machine-generated.

Researchers identified novel RNA aptamers targeting drug-resistant HIV-1 reverse transcriptase (RT). These aptamers offer new diagnostic and therapeutic strategies for resistant HIV-1 variants.

More Related Videos

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
13:47

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery

Published on: June 23, 2011

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

  • Molecular Biology
  • Virology
  • Biochemistry

Background:

  • Drug-resistant variants of HIV-1 reverse transcriptase (RT) pose significant challenges for existing therapies.
  • Anti-RT RNA aptamers have shown promise but can be ineffective against resistant strains.

Purpose of the Study:

  • To isolate and characterize novel RNA aptamers targeting drug-resistant HIV-1 RT.
  • To explore new diagnostic and therapeutic strategies for multidrug-resistant HIV-1.

Main Methods:

  • Isolation of aptamers against drug-resistant HIV-1 RT Mutant 3 (M3).
  • Binding affinity assays for aptamers against wild-type (WT) and M3 HIV-1 RT.
  • Competition assays to determine aptamer binding sites.
  • Aptamer-based microarray for distinguishing HIV-1 RT variants.

Main Results:

  • Two aptamers, M302 and 12.01, were isolated against M3 HIV-1 RT.
  • M302 showed specific binding to M3, while 12.01 bound both M3 and WT HIV-1 RT.
  • Neither aptamer inhibited polymerase or RNase H activity, suggesting a novel binding epitope.
  • Aptamers distinguished between M3 and WT HIV-1 RT on a microarray.

Conclusions:

  • Novel RNA aptamers targeting drug-resistant HIV-1 RT were identified.
  • These aptamers bind to a previously unrecognized RNA-binding epitope on HIV-1 RT.
  • Aptamer-based microarrays can differentiate HIV-1 RT drug resistance profiles.
  • This approach provides a new method for assessing HIV-1 drug resistance by probing protein conformation.